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Background: Management of late relapse of a testicular germ cell tumor is difficult because few cases have been
reported and the tumors are intractable to chemotherapy. Here we present a case with a single brain metastasis
from late relapse of a testicular germ cell tumor. This is the first report of a brain metastasis that was treated
successfully only by surgery.
Case presentation: A 19-year-old Japanese man presented with breathing difficulties and left testis enlargement
and he was diagnosed with a yolk sac tumor following a left orchiectomy. At the time of diagnosis, multiple lung
metastases were apparent on computed tomography, and serum alpha-fetoprotein level was elevated to
10,245 ng/ml. The patient received three postoperative courses of bleomycin, etoposide and cisplatin and etoposide
and cisplatin respectively and a complete response was obtained. Four years after surgery, the patient was admitted
to the hospital due to a sudden seizure. High alpha-fetoprotein levels (539 ng/ml) were evident and magnetic
resonance imaging suggested a 45-mm single brain tumor in the right parietal lobe, for which surgery was
performed. The pathological diagnosis was yolk sac tumor. The alpha-fetoprotein level remained normal at 2 months
after operation. There was no recurrence 24 months post-operation.
Conclusion: Chemoresistance and late neurotoxicity are concerns in treating brain metastasis with chemotherapy
or cerebral radiotherapy. Surgery is believed to be the optimal treatment choice if the size of the brain metastasis is
larger than 35-mm and the late relapse area is surgically accessible.
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Late relapses (LRs) of a testicular germ cell tumors (GCT)
is defined as a recurrence after complete response to treat-
ment with a subsequent disease-free interval of at least of
2 years [1]. LRs of testicular GCT are rare, with an inci-
dence rate of 3- 4% [2]. The most common sites of LR are
the retroperitoneum (47%), lungs (25%) and mediastinum
(10%) [1]. LRs also appear in cervical nodes (8%) and the
liver (6%) [1]. To date, only a few cases of brain metastases
of LR of testicular GCTs have been reported. Hence, it is
quite difficult to decide on the choice of treatment.
Herein, our experience in a case with a single brain
metastasis from a LR of a testicular GCT is described.* Correspondence: rx-nike@hotmail.co.jp
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unless otherwise stated.The patient was successfully treated with surgery alone.
This paper describes the characteristics and treatment of
LRs of testicular GCTs including brain metastases.
Case presentation
A 19-year-old Japanese man consulted a family physician
due to breathing difficulties. The left testis was enlarged
to 15 cm in diameter, and multiple lung shadows were
observed on a chest X-ray. The patient was then referred
to our institution due to suspected lung metastases of tes-
ticular cancer. Left orchiectomy was performed and he was
diagnosed with a yolk sac tumor (YST). At the time of
diagnosis, multiple lung metastases were apparent on com-
puted tomography (CT). Postorchiectomy serum levels of
tumor markers were examined, with an elevated alpha-
fetoprotein (AFP) level of 10,245 ng/ml, but otherwise nor-
mal with lactate dehydrogenase (LDH) level of 151 U/l and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 2 Hematoxylin and eosin staining of brain metastasis.
Above, low magnification image. Below, high magnifications of brain
tumor. Hematoxylin and eosin staining and positive immune-staining
for alpha-fetoprotein. The final pathological diagnosis was a yolk
sac tumor.
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L. Elevated AFP level indicated that he fulfilled the cri-
teria of poor prognosis according to the International
Germ Cell Consensus Classification [3]. The patient re-
ceived three postoperative courses of bleomycin, etopo-
side and cisplatin (BEP) and etoposide and cisplatin (EP)
respectively and a complete response was obtained. There
was no recurrence post-operatively during follow-ups at
3–6 months intervals, according to serum marker levels
and CT imaging from the chest to pelvis. Four years after
surgery, the patient was transferred to the emergency de-
partment due to a sudden seizure. High AFP levels (539
ng/ml) were evident, although other markers were nor-
mal. Magnetic resonance imaging (MRI) suggested a
45-mm single brain tumor in the right parietal lobe, and
no other tumor was evident, including the contralateral
testis (Figure 1). Surgery was performed on the single
brain metastasis. The pathological diagnosis was YST
(Figure 2). The AFP level remained normal at 2 months
after surgery. The patient has not had neurological dis-
ability. Moreover, there was no recurrence 24 months
after surgery.
Conclusions
LR can be due to a second primary tumor (either a me-
tastasis from a second testicular neoplasm or an extra-
gonadal primary tumor), a delayed transformation of aFigure 1 Magnetic resonance imaging of the brain metastasis.
Above, representative axial and coronal T1-weighed gadolinium-
enhanced Magnetic resonance imaging (MRI) slices of the brain at
the time of seizure. White arrow: brain tumor. The images reveal a
45-mm mass on the right side of the brain. Below, axial and coronal
T1-weighed gadolinium-enhanced MRI slices, taken 6 months
post-operation. Black arrow: post-treatment change after operation.metastatic teratoma into a malignant neoplasm, or per-
sistence of a microscopic viable cancer with slow-
growing tendencies [4].
Various histologies have been reported for LR: GCT
(66%), pure teratoma (17- 22%), sarcoma (6%), and adeno-
carcinoma (6%) [1,2,5]. Sixty percent of patients present
with elements of teratoma [5]. Of those patients with LR
of GCT, 44.6% are diagnosed with YSTs, which comprise
the most common GCT subtype [2]. A report by Michael
et al. included 91 patients with LR of GCT, of whom 43
had YSTs [5]. Of those 43 patients with LR of GCT, only
12 patients were diagnosed with YST as the primary neo-
plasm. Furthermore, the disease-free rates for patients
with LR during long-term follow-up were 74% for those
with LR consisting only of teratoma versus, 37% for those
with LR consisting of YST.
Testicular GCT responds well to chemotherapy, even
with brain metastases, but chemotherapy for LR has been
unsuccessful in many patients [5]. According to a study by
Baniel, 17 of 65 (26%) patients who received chemother-
apy as treatment for LRs of testicular GCTs experienced
complete responses. However, only 2 (3%) patients who
received chemotherapy alone were continuously disease-
free. Of note, these 2 patients had not previously received
cisplatin-based chemotherapy, suggesting that LR is asso-
ciated with chemoresistance [1,5]. While chemotherapy
might be effective for chemotherapy-naive patients, it does
not work for most patients with LR if they previously re-
ceived chemotherapy to treat the primary tumor. Conse-
quently, a surgical approach is the most appropriate
treatment choice. George et al. reported that 49 of 83 pa-
tients (59%) presented with no evidence of disease after
surgery for LR [6]. Twenty-one of the 49 patients (43%)
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remained continuously disease-free, while 28 of the 49 pa-
tients (57%) experienced one or more subsequent relapses.
The 5-year cause-specific survival for all cases of brain
metastasis from testicular GCT ranges from 35.9% to −53%
[7-9]. The 5-year cause- specific survival for cases of brain
metastasis at initial diagnosis was 42.9%. In contrast, the 5-
year cause-specific survival for cases of brain metastasis
after or during cisplatin-based chemotherapy was even
worse, 12% to −29.6%, indicating that brain metastases in
the latter group were chemotherapy-resistant [7-9]. In such
cases, cerebral radiotherapy or surgery might provide im-
portant benefits.
Cerebral radiotherapy has been demonstrated as a treat-
ment for brain metastases of testicular GCT, as these tu-
mors possess a certain level of radiosensitivity. Stereotactic
radiotherapy (SRT) techniques, such as GammaKnife or
CyberKnife have been used to treat brain tumors. In gen-
eral, for brain metastasis, the indication for SRT includes
tumors with a median diameter less than 3.5 cm and up to
3 small brain metastases. Metastases in the eloquent cor-
tex, basal ganglia, thalamus, and even the brainstem, a lo-
cation considered to be surgically inaccessible, can be
treated with a relatively low risk [10]. In clinical practice,
surgery should be considered for any patient with a single
brain metastasis in an accessible location, especially if the
tumor is large, the mass effect is significant, and/or ob-
structive hydrocephalus is present [11]. In our case, SRT
was not chosen because the tumor size was 4.5 cm and it
was accessible by surgery.
In whole-brain radiation therapy (WBRT) for brain me-
tastases, a total of 30 to 50 Gy, divided in 10–20 fractions
is applied, and with a single dose is 1.5 -3 Gy [8,9]. WBRT
alone could be a treatment option for patients with mul-
tiple brain metastases or poor performance status patients
[11]. WBRT is sometimes supplemented with surgery or
SRT to treat micrometastases [8,9]; however, there is no
definitive evidence of overall survival imporvement if
WBRT is performed after surgery, instead of SRT. Add-
itionally, the risk of late neurotoxicity after WBRT in long-
surviving patients is not negligible. Up to 11% of patients
who underwent WBRT experienced neurotoxicity symp-
toms, including memory loss that progressed to dementia,
frontal gait disorders, and urinary incontinence [11].
In our case, the LR of YST, discovered 4 years after oper-
ation was localized in a surgically accessible area of the pa-
tient’s brain. SRT was not chosen but a metastasectomy
was performed in consideration of the tumor size and loca-
tion. Because tumor resection was successful, chemother-
apy or cerebral radiotherapy was not applied due to
concerns about chemoresistance and late neurotoxity.
There has been no recurrence 24 months post-operation.
Thus, surgery is considered an optimal treatment choice of
the LR area if surgically accessible.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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